Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Ortega Madueño, Isabel ^a   Garcia Montojo, Marta ^a   Dominguez Mozo, Maria Inmaculada ^a   Garcia Martinez, Angel ^a   Arias Leal, Ana Maria ^a   Casanova, Ignacio ^a   Arroyo, Rafael ^a   Alvarez Lafuente, Roberto ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NATALIZUMAB; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON; BETA INTERFERON; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTOR; VIRUS ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOPATHOGENESIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RECURRENT DISEASE; TREATMENT DURATION; BLOOD; GENETICS; IMMUNOLOGY;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIOMARKERS; DISEASE PROGRESSION; FEMALE; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; NATALIZUMAB; RECURRENCE;

EID: 84905851912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104836     Document Type: Article

References (30)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple Sclerosis. N Engl J Med 343: 938-952.
2. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, et al. (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503-1511.
3. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, et al. (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8 :987-997.
4. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
5. Tselis A (2011) Evidence for viral etiology of multiple sclerosis. Semin Neurol 31: 307-316.
6. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, et al. (2001) Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286: 3083-3088. (Pubitemid 34016522)
7. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, et al. (2005) Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293: 2496-2500. (Pubitemid 40705731)
8. Salvetti M, Giovannoni G, Aloisi F (2009) Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 22: 201-206.
9. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, et al. (1995) Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 92: 7440-7444.
10. Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM (2003) Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis 187: 1365-1376. (Pubitemid 36549681)
11. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, et al. (1997) Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 3: 1394-1397. (Pubitemid 28011041)
12. Höllsberg P, Kusk M, Bech E, Hansen HJ, Jakobsen J, et al. (2005) Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity. Acta Neurol Scand 112: 395-402. (Pubitemid 41695720)
13. Alvarez-Lafuente R, Martínez A, Garcia-Montojo M, Mas A, De Las Heras V, et al. (2010) MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients. Eur J Neurol 17: 129-135.
14. Akhyani N, Berti R, Brennan MB, Soldan SS, Eaton JM, et al. (2000) Tissue distribution and variant characterization of human herpesvirus (HHV)-6: Increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis 182:1321-1325.
15. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S (2000). Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol 47:306-313. (Pubitemid 30141839)
16. Garcia-Montojo M, Dominguez-Mozo MI, De las Heras V, Bartolome M, Garcia-Martinez A, et al. (2010) Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon beta treatment in multiple sclerosis patients. A two years follow-up study. Eur J Neurol 17: 470-478.
17. Kawade Y (1986) Quantitation of neutralization of interferon by antibody. Methods Enzymol 119: 558-573.
18. Álvarez-Lafuente R, De las Heras V, Bartolomé M, Montojo-García M, Arroyo R (2006) Human Herpesvirus 6 and multiple sclerosis: a one-year follow-up study. Brain Pathology 16: 20-27.
19. Álvarez-Lafuente R, De las Heras V, Bartolomé M, Picazo JJ, Arroyo R (2004) Beta interferon treatment reduce HHV-6 viral load in multiple sclerosis relapses but not in remission. Eur Neurol 52: 87-91. (Pubitemid 39274289)
20. Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, Bartolome M, Garcia-Martinez MA, et al. (2011) Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. Eur J Neurol 18: 1027-1035.
21. Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ (2002) Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler 8: 237-242. (Pubitemid 34654060)
22. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975-990. (Pubitemid 350201788)
23. Johnson KP (1997) The historical development of interferons as multiple sclerosis therapies. J Mol Med 75: 89-94. (Pubitemid 27119488)
24. Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P (2004) Immunogenicity of interferon beta: differences among products. J Neurol 251: II15-II24.
25. Hurwitz BJ (2008) Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. J Neurol Sci 272: 8-19.
26. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double blind, placebo-controlled trial. The Copolymer-1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.
27. Racke MK, Lovett-Racke AE, Karandikar NJ (2010) The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 74: S25-S30.
28. Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64: 1336-1342. (Pubitemid 40570497)
29. Selter RC, Biberacher V, Grummel V, Buck D, Eienbröker C, et al. (2013) Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler 19: 1454-1461.
30. Simpson S Jr, Taylor B, Dwyer DE, Taylor J, Blizzard L, et al. (2012) Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult Scler 18: 799-806.